Dipeptidyl peptidase-IV inhibitors: Fixing type 2 diabetes?

British Journal of Hospital Medicine

Volumn 68, Issue 11, 2007, Pages 599-602

  McIntyre, Hugh F ^a   Grant, Paul ^a  

^a East Sussex Healthcare NHS Trust   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BIGUANIDE DERIVATIVE; DIPEPTIDYL PEPTIDASE IV; DIPEPTIDYL PEPTIDASE IV INHIBITOR; GLIPIZIDE; INCRETIN; INSULIN; METFORMIN; PIOGLITAZONE; PLACEBO; ROSIGLITAZONE; SAXAGLIPITIN; SITAGLIPTIN; SULFONYLUREA DERIVATIVE; UNCLASSIFIED DRUG; VILDAGLIPTIN;

CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DIARRHEA; DISEASE COURSE; DRUG EFFECT; DRUG POTENTIATION; DRUG SAFETY; DRUG TOLERABILITY; GLUCOSE BLOOD LEVEL; HEART INFARCTION; HUMAN; HYPERGLYCEMIA; INSULIN RELEASE; INSULIN RESISTANCE; LIFESTYLE MODIFICATION; MONOTHERAPY; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; OSTEOPOROSIS; REVIEW; TREATMENT FAILURE; WORLD HEALTH ORGANIZATION;

EID: 36649021752     PISSN: 17508460     EISSN: None     Source Type: Journal    
DOI: 10.12968/hmed.2007.68.11.27682     Document Type: Review

References (27)

1. Aschner P, Kipnes MS, Lunceford JK, Sanchez M, Mickel C, Williams-Herman DE; Sitagliptin Study 021 Group (2006) Effect of the dipeptidyl peptidase-4 inhibitor sitagliptin as monothetapy on glycemic control in patients with type 2 diabetes. Diabetes Care 29(12): 2632-7
2. Charbonnel B, Karasik A, Liu J, Wu M, Meininger G; Sitagliptin Study 020 Group (2006) Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes inadequately controlled with metformin alone. Diabetes Care 29(12): 2638-43
3. Clark WL (2006) Exenatide. From the Gila monster to you. Exenatide is the first of a new class of drugs known as "incretin mimetics" that can enhance your blood glucose control. Diabetes Self Manag 23(1): 36-40
4. DeFronzo RA, Ratner RE, Han J, Kim DD, Fineman MS, Baron AD (2005) Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes. Diabetes Care 28(5): 1092-100
5. Drucker DJ (2005) Biologic actions and therapeutic potential of the proglucagon-derived peptides. Nat Clin Pract Endocrinol Metab 1(1): 22-31
6. Fonseca V, Schweizer A, Albrecht D, Baron M, Chang I, Dejager S (2007) Addition of vildagliptin to insulin improves glycaemic control in type 2 diabetes. Diabetologia 50(6): 1148-55
7. Food and Drug Administration (2007) Exenatide (marketed as Byetta) Information. FDA Alert. www.fda.gov/cder/drug/infopage/exenatide/default.htm (accessed 20 October 2007)
8. Ford ES (2005) Risks for all-cause mortality, cardiovascular disease, and diabetes associated with the metabolic syndrome: a summary of the evidence. Diabetes Care 28(7): 1769-78
9. Gedulin BR, Nikoulina SE, Smith PA et al (2005) Exenatide (exendin-4) improves insulin sensitivity and {beta}-cell mass in insulin-resistant obese fa/fa Zucker rats independent of glycemia and body weight. Endocrinology 146(4): 2069-76
10. Hu FB, Manson JE, Stampfer MJ, Colditz G, Liu S, Solomon CG, Willett WC (2001) Diet, lifestyle, and the risk of type 2 diabetes mellitus in women. N Engl J Med 345(11): 790-7
11. International Diabetes Federation (2003) Diabetes Atlas. 2nd edn. International Diabetes Fedetation, Brussels (www.eatlas.idf.org accessed 30 October 2007)
12. Kazi D (2007) Rosiglitazone and implications for pharmacovigilance. BMJ 334: 1233-4
13. Knowler WC, Barrett-Connor E, Fowler SE, Hamman RF, Lachin JM, Walker EA, Nathan DM; Diabetes Prevention Program Research Group (2002) Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 346(6): 393-403
14. Marguet D, Baggio L, Kobayashi T et al (2000) Enhanced insulin secretion and improved glucose tolerance in mice lacking CD26. Proc Natl Acad Sci USA 97(12): 6874-9
15. Nauck M, Stockmann F, Ebert R, Creutzfeldt W (1986) Reduced incretin effect in type 2 (non-insulin-dependent) diabetes. Diabetologia 29: 46-52
16. Nauck MA, Kleine N, Orskov C Holst JJ, Willms B, Creutzfeldt W (1993) Normalisation of fasting hypoglycaemia by exogenous glucagon-like-peptide 1 (7-36 amide) in type 2 (noninsulin dependent) diabetic patients. Diabetologia 36: 741-4
17. Nauck MA, Meininger G, Sheng D, Terranella L, Stein PP; Sitagliptin Study 024 Group (2007) Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, compared with the sulfonylurea, glipizide, in patients with type 2 diabetes inadequately controlled on metformin alone: a randomized, double-blind, non-inferiority trial. Diabetes Obes Metab 9(2): 194-205
18. Nigam SK, Bush KT, Bhatnagar V (2007) Drug and toxicant handling by the OAT organic anion transporters in the kidney and other tissues. Nat Clin Pract Nephrol 3(8): 443-8
19. Pratley RE, Salsali A (2007) Inhibition of DPP-4: a new therapeutic approach for the treatment of type 2 diabetes. Curr Med Res Opin 23(4): 919-31
20. Rosenstock J, Brazg R, Andryuk PJ, Lu K, Stein P; Sitagliptin Study 019 Group (2006) Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing pioglitazone therapy in patients with type 2 diabetes: a 24-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group study. Clin Ther 28(10): 1556-68
21. Rosenstock J, Baron MA, Camisasca RP, Cressier F, Couturier A, Dejager S (2007) Efficacy and tolerability of initial combination therapy with vildagliptin and pioglitazone compared with component monotherapy in patients with type 2 diabetes. Diabetes Obes Metab 9(2): 175-85
22. Scheen AJ (2007) Glucagon-like peptide-1 (GLP-1), new target for the treatment of type 2 diabetes. Rev Med Liege 62(4): 217-21
23. Schweizer A, Couturier A, Foley JE, Dejager S (2007) Comparison between vildagliptin and metformin to sustain reductions in HbA(1c) over 1 year in drug-naive patients with Type 2 diabetes. Diabet Med 24(9): 955-61
24. UK Prospective Diabetes Study Group (1995) UKPDS 16: overview of 6 year's therapy of type 2 diabetes: a progressive disease. Diabetes 44: 1249-58
25. Vella A, Bock G, Giesler PD et al (2007) Effects of dipeptidyl peptidase-4 inhibition on gastrointestinal function, meal appearance, and glucose metabolism in type 2 diabetes. Diabetes 56(5): 1475-80
26. Wajchenberg BL (2007) Beta-cell failure in diabetes and preservation by clinical treatment. Endocr Rev 28(2): 187-218
27. Watkins PJ (2002) Guidelines for good practice in the diagnosis and treatment of non-insulin dependent diabetes mellitus. Clinical Guidelines for Type 2 Diabetes. Royal College of General Practitioners Effective Clinical Practice Unit, London